

SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- **Immunic, Inc.** (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following industry and investor conferences in November:

- November 11-13: **25<sup>th</sup> Annual BIO-Europe International Partnering Conference:** Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the 25<sup>th</sup> Annual BIO-Europe International Partnering Conference in Hamburg, Germany, on Tuesday, November 12, at 9:30 am CET.
- November 19-20: **Stifel 2019 Healthcare Conference:** Dr. Vitt will present a company overview at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19, at 8:35 am ET.
- November 20-21: **Jefferies 2019 London Healthcare Conference:** Sanjay Patel, CFA, Chief Financial Officer of Immunic, will host 1x1 meetings at the Jefferies 2019 Healthcare Conference in London on Wednesday, November 20 and Thursday, November 21.

#### **About Immunic, Inc.**

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of ROR $\gamma$ t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial planned in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: [www.immunic-therapeutics.com](http://www.immunic-therapeutics.com).

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Item 1A. Risk Factors," in the company's Current Report on Form 8-K filed on July 17, 2019, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov) or [ir.immunic-therapeutics.com/sec-filings](http://ir.immunic-therapeutics.com/sec-filings) and on request from Immunic. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

#### **Contact Information**

##### **Immunic, Inc.**

Jessica Breu  
Manager IR and Communications  
+49 89 250 0794 69  
[jessica.breu@immunic.de](mailto:jessica.breu@immunic.de)

Or

**Rx Communications Group**

Melody Carey

+1-917-322-2571

[immunic@rxir.com](mailto:immunic@rxir.com)

SOURCE Immunic, Inc.

---

<https://ir.imux.com/2019-11-05-Immunic-Inc-to-Participate-in-Industry-and-Investor-Conferences-in-November>